• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Vertex Appoints Nancy Thornberry to its Board of Directors

    12/5/23 4:01:00 PM ET
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VRTX alert in real time by email

    Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that Nancy Thornberry has been appointed to its Board of Directors as an independent director. Ms. Thornberry has more than 35 years of experience in the pharmaceutical and biotech industries, spanning drug discovery, development and commercialization. She founded and served as Chief Executive Officer of Kallyope until 2021 and remains on its Board of Directors and is Chair of Research & Development. Prior to joining Kallyope, Ms. Thornberry spent more than 30 years at Merck & Co., Inc., most recently as Senior Vice President and Global Franchise Head, Diabetes and Endocrinology, with responsibility for discovery and clinical research in diabetes, obesity and women's health. Among her many notable scientific accomplishments, Ms. Thornberry initiated and led Merck's dipeptidyl peptidase 4 (DPP-4) project, which resulted in the discovery and commercialization of JANUVIA® for the treatment of type 2 diabetes, the best-selling oral product franchise in Merck's history. She also identified the first caspase, interleukin-1β converting enzyme (ICE/caspase-1).

    "Scientific innovation is a core Vertex value and Nancy brings to our Board deep scientific expertise and a remarkable track record of discovering and developing groundbreaking medicines. Her industry experience, scientific acumen and strategic thinking will add great value to our company as we continue to expand and progress our broad and deep pipeline of novel and innovative therapies for serious diseases," said Jeffrey Leiden, M.D., Ph.D., Executive Chairman of Vertex.

    "Vertex has delivered a series of scientific breakthroughs that have resulted in life-changing medicines for patients with serious diseases such as cystic fibrosis and sickle cell disease. And today, they are on the cusp of transforming the treatment of multiple additional serious diseases," said Nancy Thornberry. "The Vertex strategy and commitment to serial innovation are delivering for patients, and I am honored to join this Board to help Vertex continue to advance its exciting pipeline."

    In addition to her role at Kallyope, Ms. Thornberry serves on the Board of Directors of Schrödinger, Inc., Denali Therapeutics Inc. and the New York Genome Center, and as an Advisor to GV (Google Ventures). Ms. Thornberry holds a Bachelor of Science in chemistry and biology from Muhlenberg College.

    About Vertex

    Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has approved medicines that treat the underlying causes of multiple chronic, life-shortening genetic diseases — cystic fibrosis, sickle cell disease and transfusion-dependent beta thalassemia — and continues to advance clinical and research programs in these diseases. Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including APOL1-mediated kidney disease, acute and neuropathic pain, type 1 diabetes and alpha-1 antitrypsin deficiency.

    Vertex was founded in 1989 and has its global headquarters in Boston, with international headquarters in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia and Latin America. Vertex is consistently recognized as one of the industry's top places to work, including 14 consecutive years on Science magazine's Top Employers list and one of Fortune's 100 Best Companies to Work For. For company updates and to learn more about Vertex's history of innovation, visit www.vrtx.com or follow us on LinkedIn, Facebook, Instagram, YouTube and Twitter/X.

    (VRTX-GEN)

    View source version on businesswire.com: https://www.businesswire.com/news/home/20231204739862/en/

    Get the next $VRTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VRTX

    DatePrice TargetRatingAnalyst
    5/7/2025Outperform → Peer Perform
    Wolfe Research
    5/6/2025$503.00Outperform → Market Perform
    Leerink Partners
    4/22/2025$535.00Overweight
    Cantor Fitzgerald
    2/12/2025$408.00 → $424.00Sell → Hold
    Canaccord Genuity
    2/11/2025Sell → Hold
    Canaccord Genuity
    1/30/2025$460.00Overweight → Equal Weight
    Wells Fargo
    12/20/2024$600.00 → $535.00Buy
    H.C. Wainwright
    12/19/2024Outperform → Perform
    Oppenheimer
    More analyst ratings

    $VRTX
    SEC Filings

    See more
    • SEC Form 144 filed by Vertex Pharmaceuticals Incorporated

      144 - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Subject)

      5/21/25 4:58:00 PM ET
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vertex Pharmaceuticals Incorporated filed SEC Form 8-K: Other Events

      8-K - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Filer)

      5/19/25 4:24:32 PM ET
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vertex Pharmaceuticals Incorporated filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Filer)

      5/14/25 4:08:09 PM ET
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VRTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP, Chief Scientific Officer Altshuler David sold $22,084 worth of shares (52 units at $424.69), decreasing direct ownership by 0.22% to 23,281 units (SEC Form 4)

      4 - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Issuer)

      5/19/25 5:07:43 PM ET
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP, COO Arbuckle Stuart A was granted 37,622 shares, increasing direct ownership by 60% to 100,611 units (SEC Form 4)

      4 - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Issuer)

      5/15/25 4:10:28 PM ET
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Upadhyay Suketu returned 1,001 shares to the company and was granted 796 shares, decreasing direct ownership by 8% to 2,354 units (SEC Form 4)

      4 - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Issuer)

      5/5/25 5:00:58 PM ET
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VRTX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • January 30, 2025 - FDA Approves Novel Non-Opioid Treatment for Moderate to Severe Acute Pain

      For Immediate Release: January 30, 2025 Today, the U.S. Food and Drug Administration approved Journavx (suzetrigine) 50 milligram oral tablets, a first-in-class non-opioid analgesic, to treat moderate to severe acute pain in adults. Journavx reduces pain by targeting a pain-signaling pathway involving sodium channels in the peripheral nervous system, before pain signals reach the brain.  Journavx is the first dr

      1/30/25 5:46:14 PM ET
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • December 8, 2023 - FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease

      For Immediate Release: December 08, 2023 Today, the U.S. Food and Drug Administration approved two milestone treatments, Casgevy and Lyfgenia, representing the first cell-based gene therapies for the treatment of sickle cell disease (SCD) in patients 12 years and older. Additionally, one of these therapies, Casgevy, is the first FDA-approved treatment to utilize a type of novel genome editing technology, signali

      12/8/23 11:12:21 AM ET
      $BLUE
      $VRTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • FDA Approval for TRIKAFTA (COPACKAGED) issued to VERTEX PHARMS INC

      Submission status for VERTEX PHARMS INC's drug TRIKAFTA (COPACKAGED) (SUPPL-11) with active ingredient ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR has changed to 'Approval' on 08/03/2023. Application Category: NDA, Application Number: 212273, Application Classification: Labeling

      8/4/23 4:36:00 AM ET
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VRTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Vertex Pharma downgraded by Wolfe Research

      Wolfe Research downgraded Vertex Pharma from Outperform to Peer Perform

      5/7/25 8:37:12 AM ET
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vertex Pharma downgraded by Leerink Partners with a new price target

      Leerink Partners downgraded Vertex Pharma from Outperform to Market Perform and set a new price target of $503.00

      5/6/25 8:04:29 AM ET
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald resumed coverage on Vertex Pharma with a new price target

      Cantor Fitzgerald resumed coverage of Vertex Pharma with a rating of Overweight and set a new price target of $535.00

      4/22/25 7:35:34 AM ET
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VRTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Vertex Presents Positive Data for Zimislecel in Type 1 Diabetes at the American Diabetes Association 85th Scientific Sessions

      – Results from the study continue to demonstrate the transformative potential of zimislecel with consistent and durable patient benefit – – All 12 patients with at least one year of follow-up who received a full dose of zimislecel as a single infusion achieved ADA-recommended target HbA1c levels <7% and >70% time-in-range (70-180 mg/dL), and 10/12 patients were insulin free – – Data presented at ADA simultaneously published in the New England Journal of Medicine – – Vertex to host investor webcast tonight, June 20, 2025, at 7:15 p.m. CT / 8:15 p.m. ET – Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced simultaneous presentation and publication of updated data from th

      6/20/25 7:15:00 PM ET
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vertex Presents New Data on Benefits of ALYFTREK® and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference

      - Oral presentation on outcomes following treatment with CFTR modulators show that improvements in CFTR function, as measured by lower sweat chloride, correlate with better outcomes for people with cystic fibrosis - - Oral presentation on new post hoc data from randomized, controlled and open-label trials suggest improved quality of life results with ALYFTREK compared to TRIKAFTA® – Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced data across multiple studies demonstrating positive clinical and quality of life benefits of treatment with CFTR modulators and, in particular, ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor), which is approved in the United States and United

      6/6/25 12:00:00 PM ET
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vertex to Participate in Upcoming Investor Conferences

      Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced management participation in three upcoming investor conferences. Susie Lisa, Senior Vice President, Investor Relations, and Manisha Pai, Executive Director, Investor Relations, will participate in the Evercore Biotechnology Summit on Wednesday, May 21, 2025. Dr. Reshma Kewalramani, Chief Executive Officer and President, will participate in a fireside chat at the Bernstein 41st Annual Strategic Decisions Conference (SDC) on Friday, May 30, 2025, at 8:00 a.m. ET. Dr. Kewalramani and Dr. David Altshuler, Executive Vice President, Global Research, and Chief Scientific Officer, will participate in a fireside chat at the Gold

      5/15/25 4:05:00 PM ET
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VRTX
    Leadership Updates

    Live Leadership Updates

    See more
    • Vertex Appoints Nancy Thornberry to its Board of Directors

      Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that Nancy Thornberry has been appointed to its Board of Directors as an independent director. Ms. Thornberry has more than 35 years of experience in the pharmaceutical and biotech industries, spanning drug discovery, development and commercialization. She founded and served as Chief Executive Officer of Kallyope until 2021 and remains on its Board of Directors and is Chair of Research & Development. Prior to joining Kallyope, Ms. Thornberry spent more than 30 years at Merck & Co., Inc., most recently as Senior Vice President and Global Franchise Head, Diabetes and Endocrinology, with responsibility for discovery and clinical

      12/5/23 4:01:00 PM ET
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vertex Appoints Michel Lagarde to its Board of Directors

      Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that Michel Lagarde has been appointed to its Board of Directors as an independent director. Mr. Lagarde is a senior health care and business leader with global expertise, currently serving as Chief Operating Officer and Executive Vice President of Thermo Fisher Scientific Inc. Prior to Thermo Fisher, Mr. Lagarde served as President and Chief Operating Officer of Patheon, a contract manufacturer to the biopharma industry, and as a Managing Director at JLL Partners, a private equity firm investing in health care services. "We are delighted to have Michel join the Vertex Board. His deep experience across numerous segments of

      10/5/23 8:00:00 AM ET
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vertex Appoints E. Morrey Atkinson, Ph.D., to EVP and Chief Technical Operations Officer, Head of Biopharmaceutical Sciences and Manufacturing Operations

      Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that E. Morrey Atkinson, Ph.D., has been appointed Executive Vice President, Chief Technical Operations Officer, Head of Biopharmaceutical Sciences and Manufacturing Operations, effective immediately. Dr. Atkinson has served as Senior Vice President of Global Commercial Manufacturing and Supply Chain since July 2020. This new role and function unifies responsibility for small molecule, cell and gene therapies across preclinical, clinical and commercial biopharmaceutical sciences, manufacturing operations and global supply chain. "Over the last three years, Morrey has played a vital role in building out our commercial manufa

      8/29/23 9:00:00 AM ET
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care